Plain-English translation of NCT05417594 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new cancer medication called to see whether it is safe, well-tolerated, and effective for people with advanced cancers. The trial will test the medication both by itself and when combined with other cancer treatments, depending on which group you join. Researchers want to find the right doses and learn how this medication works in the body.
Many advanced cancers, especially those with specific genetic mutations related to DNA repair, are difficult to treat and patients need new options. This medication is designed to target cancer cells with these mutations, and combining it with other established cancer drugs may help fight the disease more effectively.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you will take the medication as a pill or receive it in combination with another cancer drug, either alone or alongside established treatments like temozolomide. You will attend regular clinic visits for blood tests, imaging scans (like MRI), and check-ups to monitor how you are tolerating the medication and how your cancer is responding. The study lasts up to 12 cycles of treatment, with ongoing follow-up visits to track your health and safety.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States